MindMaze Therapeutics has appointed Dr John Krakauer as a strategic advisor to support its next phase of growth in the United States. 

“John has shaped the science behind our platform for years, and his foundational work is central to how we think about recovery,” said Zach Henderson, CEO of MindMaze Therapeutics. “As we scale in the United States, his counsel will help us achieve our mission to reach more patients in need of precision neurotherapeutics wherever they may be.” 

Dr Krakauer is the original scientific creator of MindPod, MindMaze Therapeutics’ precision upper-limb rehabilitation system, and one of the world’s most cited researchers in motor neuroscience, stroke recovery, and neurorehabilitation. He holds the John C Malone Professorship in Neurology, Neuroscience, and Physical Medicine and Rehabilitation at The Johns Hopkins University School of Medicine, and directs both the Brain, Learning, Animation, and Movement (BLAM) Lab and the Centre for Restorative Neurotechnology (CRN) at the Champalimaud Foundation in Lisbon, Portugal. His foundational work establishing the high-dose, high-intensity paradigm, which is the scientific basis of the MindMaze platform, has reshaped how the field approaches neuroplasticity-driven recovery. 

“The clinical case for high-dose, high-intensity neurorehabilitation is now unambiguous: the brain is a learning organ, and recovery depends on delivering the right dose and intensity of training. Health systems have historically struggled to do so, lacking a scalable platform that could deliver it reliably across every care setting, including the home. MindMaze Therapeutics has spent years turning that science into a platform clinicians can actually deploy across the care continuum, while confirming in the real world what the science always suggested: dose and intensity drive recovery. This advisory role lets me stay closely engaged in that mission while pushing the underlying research forward,” said Dr Krakauer. 

 The appointment follows a period of significant momentum for MindMaze Therapeutics, including a two-year, multi-site real-world evidence programme that demonstrated significant improvements in patient mobility and self-care, a 60% increase in therapy delivered per day and 17% higher community discharge rates compared with standard care, while 87% of patients found the neurotherapy enjoyable. The company has also established a US headquarters and Patient Experience Center at The Pearl in Charlotte’s Innovation District, and earlier this year announced a go-to-market partnership with Vibra Healthcare.